Clinical complete response to serplulimab plus bevacizumab and chemotherapy in MSS/KRAS-mutant metastatic sigmoid colon adenocarcinoma: a case report and literature review
Mismatched-repair–proficient/microsatellite-stable (pMMR/MSS) metastatic colorectal cancer (mCRC) is typically refractory to immune checkpoint inhibitors. Early randomized data suggest that adding PD-1 blockade to anti-angiogenic therapy and oxaliplatin-based chemotherapy may improve outcomes, but r...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Frontiers Media S.A.
2026-07-01
|
| Rangatū: | Frontiers in Immunology |
| Ngā marau: | |
| Urunga tuihono: | https://www.frontiersin.org/articles/10.3389/fimmu.2026.1740803/full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|